SCHEMBL5327804

SCHEMBL5327804

CC(C)(C(=N)NO)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 4/20 0.48
HDAC1 Q13547 4/20 0.48
HDAC2 Q92769 4/20 0.48
HDAC6 Q9UBN7 4/20 0.48
HDAC4 P56524 2/20 0.48
HDAC7 Q8WUI4 2/20 0.48
HDAC10 Q969S8 2/20 0.48
HDAC11 Q96DB2 2/20 0.48
HDAC8 Q9BY41 2/20 0.48
HDAC9 Q9UKV0 2/20 0.48
HDAC5 Q9UQL6 2/20 0.48
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
ALDH1A1 P00352 2/20 0.40
ALOX15 P16050 1/20 0.40
ESR1 P03372 3/20 0.39
ESR2 Q92731 3/20 0.39
CYP3A4 P08684 1/20 0.39
KCNN4 O15554 3/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL836539 0.81 ESR1 (0.48) HDAC1KMT2AALDH1A1ESR1ESR2
SCHEMBL23588109 0.79 MEN1 (0.48) HDAC1KMT2AMAPK1CYP2C19HIF1A
SCHEMBL837167 0.79 MEN1 (0.40) HDAC3HDAC1HDAC2HDAC6HDAC4
SCHEMBL10400273 0.77 PTPN1 (0.41) CYP3A4
SCHEMBL18603137 0.77 CYP19A1 (0.38) MAPTKMT2AALDH1A1CYP3A4CYP2C19
SCHEMBL3523088 0.77 KCNN4 (0.43) HDAC3HDAC1HDAC2HDAC6HDAC4
SCHEMBL24239792 0.75 MAPT (0.52) HDAC3HDAC1HDAC2HDAC6HDAC4
SCHEMBL9035777 0.74 HDAC3 (0.70) HDAC3HDAC1HDAC2HDAC6HDAC4
SCHEMBL11670668 0.74 HDAC3 (0.48) HDAC3HDAC1HDAC2HDAC6HDAC4
SCHEMBL5659757 0.74 HDAC3 (0.44) HDAC3HDAC1HDAC2HDAC6HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4452964-A1 HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER Boehringer Ingelheim International GmbH (DE) 2024-10-30 EP disclosed
WO-2023117681-A1 HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-06-29 WO disclosed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20070287699-A1 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-12-13 US disclosed
WO-2007130499-A2 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562869-B2 Oxadiazole compounds OXA1L, PSEN1, MAPT HDAC3 2470/4885HDAC1 2153/4885HDAC2 2850/4885
US-20200140400-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT HDAC3 2488/4885HDAC1 2136/4885HDAC2 2896/4885
US-20170073319-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT HDAC3 2470/4885HDAC1 2153/4885HDAC2 2850/4885
US-20070287699-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 HDAC3 1847/4885HDAC1 1861/4885HDAC2 2801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.